{
  "pmid": "41161603",
  "title": "Response to Papp et al, \"Efficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study\".",
  "abstract": "",
  "pub_date": "2025-10-27",
  "publication_types": [
    "Editorial"
  ],
  "affiliations": [
    "University of Utah Spencer F. Eccles School of Medicine, Salt Lake City, Utah.",
    "Department of Dermatology, University of Utah Spencer F. Eccles School of Medicine, Salt Lake City, Utah.",
    "Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina; Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Electronic address: Steven.Feldman@AdvocateHealth.org."
  ],
  "url": "https://pubmed.ncbi.nlm.nih.gov/41161603/",
  "snapshot_id": "2026-02-12T14-09-47Z",
  "ingested_at": "2026-02-12T14:09:51.284857+00:00"
}